Chemical formula: C₆₅H₈₉GaN₁₄O₁₈S₂ Molecular mass: 1,486.55 g/mol
Gallium ⁶⁸Ga edotreotide binds to somatostatin receptors, with highest affinity (Ki = 2.5 ± 0.5 nanomolar) for subtype 2 receptors (sstr2). Gallium ⁶⁸Ga edotreotide binds to cells that express somatostatin receptors including malignant neuroendocrine cells, which overexpress sstr2 receptors. Gallium ⁶⁸Ga edotreotide is a β+ emitting radionuclide with associated 511 keV annihilation photons that allow positron emission tomography (PET) imaging.
The relationship between gallium ⁶⁸Ga edotreotide plasma concentrations and successful imaging was not explored in clinical trials.
Gallium ⁶⁸Ga edotreotide distributes to all sstr2-expressing organs such as pituitary, thyroid, spleen, adrenals, kidney, pancreas, prostate, liver, and salivary glands. Uptake in the lung and lymph nodes are lower as compared to other sstr-2 expressing organs.
Radiotracer elimination is exclusively via urine. Approximately 16% of the injected dose is excreted in urine in the first two to four hours post-injection.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
